Investing.com - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

UPDATE 1-Vietnam seeks 31 mln doses of Pfizer-BioNTech vaccine in 2021

Published 05/14/2021, 05:37 PM
Updated 05/14/2021, 05:40 PM
© Reuters
AZN
-
AZN
-
22UAy
-
5CV
-

(Adds details, background)
By Phuong Nguyen
HANOI, May 14 (Reuters) - Vietnam is seeking 31 million
doses of the COVID-19 vaccine jointly developed by Pfizer
PFE.N and BioNTech 22UAy.DE in 2021, its health ministry
said on Friday, as the country seeks to secure its vaccines amid
competition and supply uncertainty.
By end-2021, Vietnam expects to have received a total of 110
million doses of COVID-19 vaccines, including those of
Pfizer/BioNTech, 30 million from AstraZeneca (NASDAQ:AZN) AZN.L and 38.9
million doses via the COVAX scheme, the ministry said in a
statement.
It said Vietnam had made a request for an additional 10
million doses under the COVAX initiative.
The Southeast Asian country is seeking to expedite its
domestic inoculation programme as it tackles a new outbreak that
has reached 26 of its 63 provinces.
Though it has made a slow start, its caseload remains
relatively low with just 3,756 infections and 35 deaths recorded
overall, due largely to its strong containment measures.
The health ministry said on Friday it was also in talks to
purchase the COVID-19 vaccine of German biotech firm CureVac
5CV.DE .
Reuters on Wednesday reported the World Health Organization
was reviewing a proposal by an unidentified vaccine manufacturer
in Vietnam to become an mRNA-based COVID-19 vaccine technology
hub in the Southeast Asian country.
Vietnam's homegrown vaccine, Covivac, is expected to be
available by 2022, the government said.
Neighbour Philippines said on Friday it was aiming to secure
40 million doses of the Pfizer/Biotech vaccine, in what could be
its first supply agreement. Earlier this month it received
190,000 shots of the same vaccine via COVAX.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.